Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response

Sánchez-Rovira, P; Seguí, MA; Llombart, A; Aranda, E; Antón, A; Sánchez, A; Lomas, M; Jaén, A; Fernández, M; Porras, I; Dalmau, E; Morales, S; Haba-Rodríguez, J de la.
Clin. transl. oncol. (Print) ; 15(10): 810-817, oct. 2013. tab, ilus
Artículo en Inglés | IBECS (España) | ID: ibc-127504

Documentos relacionados

  1. Bacteria in tumors "hit the road" together.
  2. Deciphering breast cancer: from biology to the clinic.
  3. Tissue-resident FOLR2<sup>+</sup> macrophages associate with CD8<sup>+</sup> T cell infiltration in human breast cancer.
  4. Tumor-resident intracellular microbiota promotes metastatic colonization in breast cancer.
  5. Comparison of Clinical Outcomes Between Low- and High-Risk Groups of Early Breast Cancer Patients Treated with Intraoperative Radiotherapy in Addition to External Beam Radiation: A Multi-Centre Prospective Study.
  6. [The place of radiotherapy].
  7. A Precise Approach for Radiotherapy of Breast Cancer.
  8. Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial - Authors' reply.
  9. Treatment time interval in breast cancer: A population-based study on the impact of type and number of cancer centres attended.
  10. Next-generation sequencing in breast pathology: real impact on routine practice over a decade since its introduction.